| Net Cash Provided by (Used in) Operating Activities |
$17,085 |
USD |
9% |
Q1 2025 |
Q1 2025 |
| Net Cash Provided by (Used in) Financing Activities |
$50,000 |
USD |
166% |
Q1 2025 |
Q1 2025 |
| Common Stock, Shares Authorized |
2,499,900,000 |
shares |
0% |
Q3 2025 |
Q3 2025 |
| Common Stock, Shares, Issued |
63,931,929 |
shares |
-88% |
Q3 2025 |
Q3 2025 |
| Common Stock, Par or Stated Value Per Share |
0 |
USD/shares |
0% |
Q3 2025 |
Q3 2025 |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect |
$32,915 |
USD |
|
Q1 2025 |
Q1 2025 |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
$4,602 |
USD |
|
Q3 2025 |
Q3 2025 |
| Interest Paid, Excluding Capitalized Interest, Operating Activities |
$46,800 |
USD |
|
Q1 2025 |
Q1 2025 |
| Deferred Tax Assets, Valuation Allowance |
$838,455 |
USD |
|
Q3 2025 |
Q3 2025 |
| Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent |
0.21 |
pure |
|
Q1 2025 |
Q1 2025 |
| Deferred Tax Assets, Gross |
$838,455 |
USD |
|
Q3 2025 |
Q3 2025 |
| Deferred Tax Assets, Operating Loss Carryforwards |
$650,165 |
USD |
-4.4% |
Q4 2024 |
FY 2024 |
| Current Income Tax Expense (Benefit) |
$728,927 |
USD |
|
Q1 2025 |
Q1 2025 |
| Unrecognized Tax Benefits |
$0 |
USD |
|
Q4 2024 |
FY 2024 |
| Additional Paid in Capital |
$3,938,196 |
USD |
99% |
Q3 2025 |
Q3 2025 |